VAERS Explorer
Back to explore

Report #2889932

Received Mar 19, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
23 yrs
State
Recovered
Unknown
Vaccinated
May 18, 2025
Onset
May 19, 2025
Days to onset
1
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.23004298PO / MO

Symptoms (8)

AstheniaChillsHeadacheHot flushMigraineNauseaPhotophobiaTremor

Symptom narrative

being super shaky; Hot flashes; chills; super weak; the patient had really bad nausea, along with the headache; the patient had really bad nausea, along with the headache; Migraine; head was pounding; Case reference number US-BN-2025-000963 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV25-1178) on 21-May-2025 and concerns female patient (DOB: XX-Jan-2002). The patient's medical history and concomitant medication details were not provided. On 18-May-2025, the patient took first dose of Vivotif (batch number: 3004298), at unknown dose, orally for unknown indication. On 19-May-2025, the patient had a severe migraine, and patient head was 'pounding' and could not get out of bed and had to stay in a dark room all day. On 20-May-2025, the patient took second dose of Vivotif (batch number: 3004298), at unknown dose, orally. On unspecified date, reported as yesterday, the patient had really bad nausea, along with headache. On unspecified date, reported as today, the patient had same thing. Patient also reported being super shaky, super weak, having chills and hot flashes. On an unspecified date, the patient took aspirin for the headache. At the time of the initial report, it was unknown if the patient recovered from the events of 'migraine', 'headache', 'nausea', 'nervousness', 'weakness', 'chills' and 'hot flashes'. The reporter assessed the events of 'migraine', 'headache', 'nausea', 'nervousness', 'weakness', 'chills' and 'hot flashes' as non-serious. The reporter assessed the events of 'migraine', 'headache', 'nausea', 'nervousness', 'weakness', 'chills' and 'hot flashes' as possibly related to Vivotif. No further information was provided.; Reporter's Comments: A female patient (DOB: XX-Jan-2002) experienced non-serious events of migraine, head was pounding, could not get out of bed and had to stay in a dark room all day, on the day 1 after the patient took the first dose of Vivotif for unknown indication. On unspecified date after the patient took the second dose of Vivotif, the patient experienced non-serious events of nausea along with headache. Also, on unspecified date, the patient had same thing, and the patient experienced non-serious events of super shaky, super weak, having chills and hot flashes. Nausea and headache are listed and expected for Vivotif per CCDS v8 and USPI, whilst migraine, nervousness and hot flush are unlisted and unexpected. Chills and asthenia are listed and unexpected. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering plausible temporal relationship and since the contributory role of the suspect vaccine cannot be excluded, the reported events have been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: A female patient (DOB: 19-Jan-2002) experienced non-serious events of migraine, head was pounding, could not get out of bed and had to stay in a dark room all day, on the day 1 after the patient took the first dose of Vivotif for unknown indication. On unspecified date after the patient took the second dose of Vivotif, the patient experienced non-serious events of nausea along with headache. Also, on unspecified date, the patient had same thing, and the patient experienced non-serious events of super shaky, super weak, having chills and hot flashes. Nausea and headache are listed and expected for Vivotif per CCDS v8 and USPI, whilst migraine, nervousness and hot flush are unlisted and unexpected. Chills and asthenia are listed and unexpected. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering plausible temporal relationship and since the contributory role of the suspect vaccine cannot be excluded, the reported events have been considered as related to Vivotif. This case is considered as non-serious.

Medical history

Comments: None